BOKU - Universität für Bodenkultur Wien - Forschungsinformationssystem

Logo BOKU-Forschungsportal

Gewählte Publikation:

Trkola, A; Kuster, H; Rusert, P; Joos, B; Fischer, M; Leemann, C; Manrique, A; Huber, M; Rehr, M; Oxenius, A; Weber, R; Stiegler, G; Vcelar, B; Katinger, H; Aceto, L; Günthard, HF.
(2005): Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies.
Nat Med. 2005; 11(6):615-622 FullText FullText_BOKU

To determine the protective potential of the humoral immune response against HIV-1 in vivo we evaluated the potency of three neutralizing antibodies (2G12, 2F5 and 4E10) in suppressing viral rebound in six acutely and eight chronically HIV-1-infected individuals undergoing interruption of antiretroviral treatment ( ART). Only two of eight chronically infected individuals showed evidence of a delay in viral rebound during the passive immunization. Rebound in antibody-treated acutely infected individuals upon cessation of ART was substantially later than in a control group of 12 individuals with acute infection. Escape mutant analysis showed that the activity of 2G12 was crucial for the in vivo effect of the neutralizing antibody cocktail. By providing further direct evidence of the potency, breadth and titers of neutralizing antibodies that are required for in vivo activity, these data underline both the potential and the limits of humoral immunity in controlling HIV-1 infection.
Autor*innen der BOKU Wien:
Katinger Hermann
Find related publications in this database (using NML MeSH Indexing)
Acute Disease -
Adult -
Anti-HIV Agents - administration & dosage
Antibodies, Monoclonal - therapeutic use
Chronic Disease -
Female -
HIV Antibodies - therapeutic use
HIV Infections - therapy
HIV-1 - genetics
Humans -
Immunization, Passive -
Male -
Middle Aged -
Mutation -
Viral Load -
Virus Replication -

© BOKU Wien Impressum